A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes by Platzbecker, U, Symeonidis, A, Oliva, E N, Goede, J S, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J

Get full text

A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS) by Platzbecker, U, Symeonidis, A, Oliva, E, Goede, J, Delforge, M, Mayer, J, Slama, B, Badre, S, Gasal, E, Mehta, B, Franklin, J

Get full text

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial by Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Subbiah, Vivek

Get full text

42 - A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in Low or Intermediate-1 (INT-1) Risk Myelodysplastic Syndromes (MDS) by Platzbecker, U., Symeonidis, A., Oliva, E., Goede, J., Delforge, M., Mayer, J., Slama, B., Badre, S., Gasal, E., Mehta, B., Franklin, J.

Get full text

Listeria species escape from the phagosomes of interleukin-4-deactivated human macrophages independent of listeriolysin by Neumann, Katja, Eppler, Elisabeth, Filgueira, Luis, Groscurth, Peter, Gasal, Eduard, Schaffner, Andreas, Schoedon, Gabriele, Schneemann, Markus

Get full text

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis by Planchard, David, Besse, Benjamin, Groen, Harry J.M., Hashemi, Sayed M.S., Mazieres, Julien, Kim, Tae Min, Quoix, Elisabeth, Souquet, Pierre-Jean, Barlesi, Fabrice, Baik, Christina, Villaruz, Liza C., Kelly, Ronan J., Zhang, Shirong, Tan, Monique, Gasal, Eduard, Santarpia, Libero, Johnson, Bruce E.

Get full text

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG) by Subbiah, Vivek, Stein, Alexander, van den Bent, Martin, Wick, Antje, de Vos, Filip Y., von Bubnoff, Nikolas, van Linde, Myra E., Lai, Albert, Prager, Gerald W., Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A., Kim, Tae Min, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C., Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Wen, Patrick Y.

Get full text

BRAF -Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer by Middleton, Gary, Yang, Yiqun, Campbell, Catarina D, André, Thierry, Atreya, Chloe E, Schellens, Jan H M, Yoshino, Takayuki, Bendell, Johanna C, Hollebecque, Antoine, McRee, Autumn J, Siena, Salvatore, Gordon, Michael S, Tabernero, Josep, Yaeger, Rona, O'Dwyer, Peter J, De Vos, Filip, Van Cutsem, Eric, Millholland, John M, Brase, Jan C, Rangwala, Fatima, Gasal, Eduard, Corcoran, Ryan B

Get full text

Dabrafenib plus trametinib in patients with BRAF V600E -mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial by Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Subbiah, Vivek

Get full text